scholarly journals Transcutaneous Electrical Acupoint Stimulation (Teas) In The Treatment of Dry Eye Disease

2022 ◽  
Author(s):  
Xiaotong Ren ◽  
Jiarui Yang ◽  
Hao Yuan ◽  
Rong Zhang ◽  
Xuemin Li
Keyword(s):  
Dry Eye ◽  
Therapeutic Option ◽  
Signs And Symptoms ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Blurred Vision ◽  
Before And After ◽  
Peking University ◽  
Symptoms And Signs ◽  
Acupoint Stimulation

Abstract Purpose: To assess effectiveness and safety of the Transcutaneous Electrical Acupoint Stimulation (TEAS) treatment in alleviating symptoms and signs of dry eye disease (DED).Methods: Patients diagnosed with DED at the Peking University Third Hospital Eye Center from December 2020 to February 2021 were randomly assigned in a 1:1:1 ratio to 5mA, 3mA, or 0mA Group respectively. DED signs and symptoms were evaluated before and 30min after treatment. We compared the clinical improvement among the three groups and between each two groups. Results: A total of 63 patients were included. 5mA Group had best efficacy in all the signs and most of symptoms (P<0.05), and the symptoms scores in 3mA Group were also significantly improved after treatment except pain, watering and increased secretions (P<0.05). In the comparisons between before and after treatment between each two groups, 5mA Group showed greater improvement in the signs and most of symptoms than other two groups(P<0.05). In addition, 3mA Group had greater improvement than 0mA Group in the symptoms of asthenopia (P=0.018) and blurred vision (P=0.001). During the treatment, we hadn’t gotten any adverse events from patients.Conclusions: TEAS treatment was effective in the treatment of DED, and 5mA provided greater signs and symptoms relief. TEAS might be a new therapeutic option for the treatment of DED.

scholarly journals Dry eye disease among Glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Miraf Sahlu ◽  
Abeba T. Giorgis
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Signs And Symptoms ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Eye Drops ◽  
Schirmer Test ◽  
Ocular Surface Disease Index ◽  
Cross Sectional ◽  
Corneal Staining

Abstract Background Dry eye disease is a multifactorial disease; causing various ocular symptoms with potential damage to the ocular surface. Applying hypotensive eye drops are presumed to initiate or exacerbate existing dry eye disease. The purpose of this study was to determine the frequency of signs and symptoms and severity of dry eye disease among glaucoma patients on topical hypotensive medications and controls. Methods A cross-sectional comparative study, involving 320 glaucoma patients and controls. Ocular Surface Disease Index (OSDI) symptoms score and Schirmer, tear breakup time and corneal staining tests were used to assess dry eye disease. Data was analyzed using SPSS version 24 software; p-value less than 0.05 was considered as statistically significant. Results Among the 160 study glaucoma patients, the mean duration of topical hypotensive medication use was 5.2 ± 5.21 years (range, 4 months - 32 years). Mild to severe level of OSDI score was found in 122 (76%) glaucoma patients and in 137 (86%) controls (p = 0.033). Mild to sever abnormal clinical tests in the glaucoma patients and control, respectively, were 106 (66%) vs 80 (50%) corneal staining (p = 0.045), 79 (49%) vs 72 (45%) TBUT (p = 0.021), and 91 (57%) vs 83 (52%) Schirmer test (p = 0.242). Test results at the level of sever: 2 (1%) vs 0 (0%) corneal staining, 50 (31%) vs 39 (24%) TBUT and 65 (41%) vs 60 (38%) Schirmer test in the glaucoma patents and controls, respectively. Corneal staining and TBUT had correlation with the number of drugs (p = 0.004 and 0.031, respectively), and more relationship of the two tests with total number of drops applied per day (p = 0.01 and p <  0.001, respectively). Patients on pilocarpine and timolol had more corneal staining and lower TBUT [(p = 0.011 and p <  0.001) and (p = 0.04 and 0.012), respectively]. Conclusions The study has identified glaucoma patients to be more affected by dry eye disease than non-glaucoma patients, and presence of significantly lower TBUT and higher corneal staining in the glaucoma patients on multidrops and multidose per day. We recommend consideration of evaluation and management of DED for glaucoma patients on multidrops and multidose hypotensive medications.

scholarly journals The Association between Tear Film Thickness as Measured with OCT and Symptoms and Signs of Dry Eye Disease: A Pooled Analysis of 6 Clinical Trials

2020 ◽  
Vol 9 (11) ◽  
pp. 3791
Author(s):  
Gerhard Garhöfer ◽  
Valentin Aranha Dos Santos ◽  
Hannes Stegmann ◽  
Doreen Schmidl ◽  
Narine Adzhemian ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Film Thickness ◽  
Dry Eye ◽  
Tear Film ◽  
Pooled Analysis ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Break Up ◽  
Symptoms And Signs ◽  
Schirmer I Test

Purpose: To determine the association between tear film thickness (TFT) as measured with ultra-high resolution optical coherence tomography (UHR-OCT) and signs and symptoms of dry eye disease (DED). Methods: A total of 450 eyes from 225 patients with DED from six different randomized clinical trials were included in this pooled analysis. In all subjects, TFT was measured with a custom-built UHR-OCT system. Symptoms of DED were quantified using a standardized Ocular Surface Disease Index (OSD)I questionnaire and clinical signs including tear film break up time (TFBUT) and Schirmer I test were assessed. Associations of the average TFT with OSDI, TFBUT, and Schirmer I test were calculated using a linear regression analysis. Results: The average TFT of the included sample (mean age, 45.0 ± 13.3 years; 65% female) was 4.2 ± 0.5 µm and the OSDI 36.2 ± 10.4. A significant negative correlation was found between TFT and OSDI (r = −0.36 to −0.31; p < 0.001). Tear break up time and Schirmer I test were not correlated with OSDI. Significant albeit weak correlations were found between TFT and TFBUT (r = 0.17 to 0.25; p < 0.01) as well as Schirmer I (r = 0.36 to 0.37; p < 0.001). Subgroup analysis revealed that the correlation was stronger in the subjects with abnormal Schirmer I (<15 mm; r = 0.50 to 0.54; p < 0.001). Conclusions: The present study demonstrates an objective measurement of TFT using a novel OCT approach for DED that correlates with symptoms and signs of DED. Our data are consistent with the idea that TFT represents the aqueous-deficient component of DED.

Gender-Specific Differences in Signs and Symptoms of Dry Eye Disease

2020 ◽  
pp. 1-8
Author(s):  
Maria Borrelli ◽  
Andreas Frings ◽  
Gerd Geerling ◽  
David Finis
Keyword(s):  
Dry Eye ◽  
Signs And Symptoms ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Gender Specific Differences ◽  
Gender Specific

Advancing age does not strongly correlate with symptoms and signs of Dry Eye Disease in a large Norwegian cohort

2015 ◽  
Vol 93 ◽  
pp. n/a-n/a
Author(s):  
R.A. Badian ◽  
J.R. Eidet ◽  
S. Raeder ◽  
Ø. Utheim ◽  
X. Chen ◽  
...  
Keyword(s):  
Dry Eye ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Symptoms And Signs

Classifying signs and symptoms of dry eye disease according to underlying mechanism via the Delphi method: the DIDACTIC study

2019 ◽  
Vol 103 (10) ◽  
pp. 1475-1480 ◽  
Author(s):  
Marc Labetoulle ◽  
Tristan Bourcier ◽  
Serge Doan
Keyword(s):  
Dry Eye ◽  
Signs And Symptoms ◽  
Underlying Mechanism ◽  
Meibomian Gland ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Eyelid Margin ◽  
Mixed Treatment ◽  
Evaporative Dry Eye ◽  
Initial List

Background/aimsDry eye disease (DED) is categorised by pathophysiology as aqueous deficient dry eye (ADDE), evaporative dry eye (EDE) or mixed. Treatment should be tailored to DED pathophysiology, but this is challenging to determine. This Delphi consultation aimed to categorise and weight signs and symptoms to help identify the evaporative or aqueous deficient DED origin.MethodsA panel of French DED experts created an initial list of 77 DED signs and symptoms. In a Delphi consultation, experts categorised items by DED pathophysiology. Likert scoring was used to indicate whether items were strongly or moderately indicative of ADDE or EDE. Items could also be judged non-applicable to DED, with the opportunity to suggest alternative diagnoses.ResultsExperts attributed 19 items (of which 11 were strongly indicative) to a pathophysiology of EDE and 12 items (of which four were strongly indicative) to ADDE. Items scored strongly indicative with agreement >90% for EDE were previous chalazia, rosacea/rhinophyma, telangiectasias of eyelid margin and thick non-expressible meibomian gland secretions, and for ADDE were Sjögren syndrome or associated disease, and Schirmer <5 mm after 5 min (without anaesthesia). Seventeen items indicated neither pathophysiology and 18 items were found to be suggestive of alternative diagnoses.ConclusionsThis Delphi consultation categorised signs and symptoms, using an innovative weighting system to identify DED pathophysiology. An algorithm integrating the weighting of each sign and symptom of an individual patient would be valuable to help general ophthalmologists to classify the DED subtype and tailor treatment to DED underlying mechanism.

scholarly journals Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Klemens Fondi ◽  
Piotr A. Wozniak ◽  
Doreen Schmidl ◽  
Ahmed M. Bata ◽  
Katarzyna J. Witkowska ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Dry Eye ◽  
Sodium Hyaluronate ◽  
Signs And Symptoms ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Quality Of Sleep ◽  
Pro Re Nata ◽  
Breakup Time

Purpose. This randomized, observer-masked, crossover study investigated the effect of two hyaluronic acid/trehalose-based containing formulations, with different physical properties, on the signs and symptoms in patients with moderate to severe dry eye disease (DED). Methods. In one group, patients received a mixture of sodium hyaluronate and trehalose (HT, Thealoz Duo®) for use during the day. In the other group, patients received a more viscous formulation consisting of hyaluronic acid, trehalose, and carbomer (HTC-gel, Thealoz Duo Gel) to use pro re nata. Both groups used HTC-gel before going to bed. Clinical standard tests for DED were performed at the beginning and end of each one-week period. Further, patient satisfaction including quality of sleep was assessed using a visual analogue scale. Results. Corneal fluorescein and conjunctival lissamine green staining scores decreased, and tear breakup time (BUT) increased for both groups (p<0.001 each). Mean instillation frequency was 3.1 ± 2.6 drops/day when using HT and 1.9 ± 2.2 drops/day when using HTC-gel (p=0.02). A significant improvement in the quality of sleep was observed with both treatments (p=0.01). Conclusions. Our results show improvement in signs and symptoms of DED in both groups. While instillation of HTC-gel resulted in a lower instillation frequency, both formulations of trehalose showed good clinical efficacy. This trial is registered with NCT02980913.

Sign in / Sign up

Export Citation Format

Share Document